6533b85cfe1ef96bd12bc17b
RESEARCH PRODUCT
Analysis and comparison of autologous platelet-rich plasma preparation systems used in the treatment of enthesopathies: A preliminary study
Sylwia PłaczkowskaJarosław WitkowskiPaweł ReichertMaciej DejnekPiotr MorasiewiczEwa BargHelena Moreirasubject
Blood PlateletsMaleVascular Endothelial Growth Factor APlatelet-derived growth factormedicine.medical_treatmentPopulationMedicine (miscellaneous)EnthesopathyGeneral Biochemistry Genetics and Molecular Biologyplatelet-derived growth factorTransforming Growth Factor beta1AndrologyLeukocyte Countchemistry.chemical_compoundEpidermal growth factorgrowth factorsInternal MedicinemedicineHumansPharmacology (medical)PlateleteducationGenetics (clinical)Whole bloodeducation.field_of_studyEpidermal Growth FactorPlatelet-Rich Plasmabusiness.industryGrowth factorVascular endothelial growth factorchemistryPlatelet-rich plasmaReviews and References (medical)businessdescription
Background Autologous platelet-rich plasma (PRP) injection is an alternative but widely accepted method for the treatment of degenerative changes in tendon attachments known as enthesopathies. The PRP is considered a safe source for high concentrations of the growth factors involved in the healing process. Despite initial promising outcomes, many recent studies report conflicting results for this treatment. This may be due to differences in the concentrations of platelets and growth factors in PRPs obtained using different methods. Objectives The aim of this study was to compare PRP preparation systems in terms of morphotic components and selected growth factors to find the most appropriate procedure for the treatment of enthesopathies. Material and methods Whole blood samples from 6 healthy male volunteers were collected. Using different commercial kits (Mini GPS III System, Arthrex ACP, and Xerthra, Dr. PRP), 4 PRPs were prepared from the blood of each participant. All samples were analyzed for the content of morphotic components and the following growth factors: transforming growth factor-β1 (TGF-β1), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and platelet-derived growth factor AA (PDGF-AA). Results The Mini GPS III produced PRP with the highest concentration of platelets and white blood cells (WBC) compared to the other systems included in the study. Significant differences in the levels of EGF and PDGF-AA were found only between the Mini GPS III and Arthrex ACP. There was positive correlation between the content of platelets and the levels of PDGF-AA and EGF. The red blood cells (RBC) concentration positively correlated with PDGF-AA, EGF and VEGF. Conclusion This study showed differences between the morphotic components and levels of selected growth factors in PRP obtained with the different preparation methods. Due to insufficient data, we cannot argue for or against any of the studied protocols for the treatment of enthesopathy. Further studies on a larger population are required to validate our results.
year | journal | country | edition | language |
---|---|---|---|---|
2021-06-11 | Advances in Clinical and Experimental Medicine |